We are live on ! Find out more
SM

Sabby Management Portfolio holdings

AUM $45.1M
1-Year Est. Return 74.25%
This Fund
S&P 500
This Quarter Est. Return
-3.5%
1 Year Est. Return
-74.25%
3 Year Est. Return
-95.86%
5 Year Est. Return
-99.36%
10 Year Est. Return
-99.46%
AUM
$1.82B
AUM Growth
-$609M
Cap. Flow
-$347M
Cap. Flow %
-19.1%
Top 10 Hldgs %
52.59%
Holding
435
New
56
Increased
93
Reduced
114
Closed
122

Top Buys

Rank Stock Value
1
ALKS icon
Alkermes
ALKS
+$9.22M
2
TBRA
Tobira Therapeutics, Inc. Common Stock
TBRA
+$7.3M
3
GWPH
GW Pharmaceuticals Plc American Depositary Shares
GWPH
+$7.22M
4
UTHR icon
United Therapeutics
UTHR
+$5.06M
5
LUMO
Lumos Pharma, Inc. Common Stock
LUMO
+$4.98M

Top Sells

Rank Stock Value
1
BIIB icon
Biogen
BIIB
+$22.6M
2
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$18.2M
3
VTRS icon
Viatris
VTRS
+$18.1M
4
PXD
Pioneer Natural Resource Co.
PXD
+$15M
5
EW icon
Edwards Lifesciences
EW
+$11.6M

Sector Composition

Rank Sector Weight
1 Healthcare 10.47%
2 Technology 0.45%
3 Consumer Staples 0.1%
4 Industrials 0.09%
5 Materials 0.03%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
RXII
176
PUT
DELISTED
GALENA BIOPHARMA INC COM
RXII
$1.01M 0.06%
6,842
+10
+0.1% +$1.47K
CBAY
177
DELISTED
Cymabay Therapeutics
CBAY
$1M 0.06%
593,900
+300,606
+102% +$490K
HTWR
178
DELISTED
HEARTWARE INTERNATIONAL INC COM STK (DE)
HTWR
$1M 0.06%
19,900
+2,400
+14% +$113K
HTWR
179
PUT
DELISTED
HEARTWARE INTERNATIONAL INC COM STK (DE)
HTWR
$1M 0.06%
199
– –
RCKT icon
180
Rocket Pharmaceuticals
RCKT
$334M
$993K 0.05%
21,913
-5,587
-20% -$243K
ELGX
181
DELISTED
Endologix Inc
ELGX
$990K 0.05%
10,000
– –
OPK icon
182
Opko Health
OPK
$1.12B
$983K 0.05%
97,811
-517,346
-84% -$5.19M
PGEN icon
183
CALL
Precigen
PGEN
$1.96B
$980K 0.05%
328
– –
OPK icon
184
PUT
Opko Health
OPK
$1.12B
$958K 0.05%
953
-5,503
-85% -$55.2K
NUROW
185
DELISTED
NeuroMetrix, Inc. Warrants
NUROW
$953K 0.05%
+38,973
New +$2.12M
VTVT icon
186
vTv Therapeutics
VTVT
$125M
$952K 0.05%
3,494
-520
-13% -$146K
NTRA icon
187
Natera
NTRA
$36.1B
$936K 0.05%
86,623
+100
+0.1% +$951
ANTH
188
CALL
DELISTED
Anthera Pharmaceuticals, Inc.
ANTH
$928K 0.05%
250
– –
MNKD icon
189
MannKind Corp
MNKD
$1.19B
$922K 0.05%
127,181
+116,421
+1,082% +$1.43M
ATRS
190
DELISTED
Antares Pharma, Inc.
ATRS
$918K 0.05%
758,718
+36,151
+5% +$50.3K
NVAX icon
191
PUT
Novavax
NVAX
$1.21B
$906K 0.05%
54
-367
-87% -$56.5K
CYNA
192
DELISTED
CYNAPSUS THERAPEUTICS INC COM PAR NO PAR (CANADA)
CYNA
$905K 0.05%
58,610
+6,441
+12% +$97.9K
LXRX icon
193
Lexicon Pharmaceuticals
LXRX
$1.03B
$901K 0.05%
67,710
-193,885
-74% -$2.38M
CLVS
194
CALL
DELISTED
Clovis Oncology, Inc.
CLVS
$875K 0.05%
+250
New +$16.1K
CRDF icon
195
Cardiff Oncology
CRDF
$60.3M
$865K 0.05%
2,224
-554
-20% -$217K
BDSI
196
CALL
DELISTED
BioDelivery Sciences International, Inc.
BDSI
$862K 0.05%
1,800
+1,342
+293% +$7.61K
BDSI
197
PUT
DELISTED
BioDelivery Sciences International, Inc.
BDSI
$862K 0.05%
1,800
+1,011
+128% +$5.73K
OCUL icon
198
Ocular Therapeutix
OCUL
$1.83B
$843K 0.05%
90,000
-15,190
-14% -$164K
ACGN
199
CALL
DELISTED
Aceragen Inc
ACGN
$836K 0.05%
20
+1
+5% +$447
GNCA
200
DELISTED
Genocea Biosciences, Inc.
GNCA
$823K 0.05%
19,517
-71,626
-79% -$3.41M
6 7
8
9 10

Similar funds

CG
Circumference Group Little Rock, Arkansas $44.6M AUM 5.21% 1-Year Est. Return
OC
Optimas Capital Central, Hong Kong $44.5M AUM 24.43% 1-Year Est. Return
ICCON
Investment Counsel Company of Nevada Las Vegas, Nevada $44.5M AUM 21.97% 1-Year Est. Return
PCM
Prentice Capital Management Greenwich, Connecticut $45.7M AUM 2.65% 1-Year Est. Return
CAS
CTC Alternative Strategies Chicago, Illinois $44M AUM 43.15% 1-Year Est. Return
CM
Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return
MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
CTC
Corundum Trust Company Sioux Falls, South Dakota $43.8M AUM 20.07% 1-Year Est. Return

Sabby Management's Q4 2015 Portfolio in Review

As of Q4 2015, Sabby Management held 435 positions worth $1.82B, down 25% from $2.43B the previous quarter. Its ten largest holdings account for 53% of the portfolio.

Sabby Management withdrew a net $347M in Q4 2015, closing 122 positions and reducing 114 holdings. Its most notable exit was Biogen, an estimated $22.6M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 10% of assets, down from 13% a quarter earlier, followed by Technology and Consumer Staples.

Against the trend, Sabby Management opened a new position in Alkermes worth $10.5M.

  • Sabby Management's largest Q4 2015 buy was Alkermes: 131,671 shares worth $10.5M.
  • Sabby Management added most to Tobira Therapeutics, Inc. Common Stock in Q4 2015, an estimated $7.3M increase.
  • Sabby Management's biggest Q4 2015 reduction was Edwards Lifesciences, cutting an estimated $11.6M.
  • Sabby Management fully exited Biogen in Q4 2015, selling an estimated $22.6M.
  • Sabby Management's ten largest holdings make up 53% of its $1.82B portfolio in Q4 2015.
  • Sabby Management opened 56 new positions and closed 122 in Q4 2015.
  • Sabby Management's portfolio value fell 25% quarter-over-quarter to $1.82B.

Based on Sabby Management's 13F filing for Q4 2015, filed 16 Feb 2016.